What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
7 older updates are outside this window. Show all time
- RespiratoryGLOBAL2026-05-012025 → 2026Asthma
The 2026 GINA report's headline addition is a set of four new flowcharts covering assessment, treatment and follow-up of acute asthma and exacerbations in adults, adolescents and children aged 6-11, in both primary and acute care settings. It also adds consensus guidance on which treatment step to start children aged 6-11 at, revised advice on biologics, oxygen saturation targets, SABA dosing and using ICS-formoterol instead of SABA for mild exacerbations, plus a stronger push to minimise oral corticosteroid exposure.
- RespiratoryGLOBAL2025-11-102025 → 2026COPD
The 2026 GOLD report widens the 'exacerbator' label so a single moderate or severe exacerbation in the past year now counts (previously two or more were needed), reframes the ABE assessment around disease activity, stability and control, revises the exacerbation-severity classification, and positions high-flow nasal therapy as a first-line respiratory support option in exacerbations. A new chapter on emerging technology and artificial intelligence in COPD was also added.
- RespiratoryUS2025-07-012013 → 2025Lung cancer
Replacing the 2013 CHEST guideline on stage I and II NSCLC, the 2025 version backs minimally invasive resection over open thoracotomy on the strength of a new meta-analysis showing better overall survival, and accepts sublobar resection as equivalent to lobectomy for peripheral tumours of 2 cm or less. It also recommends adjuvant chemotherapy after complete resection of stage II disease and adjuvant targeted therapy for resected stage IB tumours carrying EGFR exon 19 deletion or L858R mutations.
source ↗curation confidence 90% - RespiratoryUS2025-07-012019 → 2025Community-acquired pneumonia
The 2025 ATS guideline reverses the 2019 position that every adult with CAP and a positive influenza test should receive antibiotics, now suggesting antibiotics be withheld in otherwise healthy patients with a positive viral test. It also accepts lung ultrasound as an alternative to chest radiography where the preferred imaging is unavailable and staff are trained, supports stopping empiric antibiotics at 48-72 hours in patients with low procalcitonin and early clinical stability, and splits the steroid advice by severity: against systemic corticosteroids in non-severe inpatient CAP, in favour of them in severe CAP.
source ↗curation confidence 90% - RespiratoryGLOBAL2025-04-152022 → 2025Tuberculosis
The 2025 edition supersedes the December 2022 update that introduced BPaLM, adding a recommendation for a new all-oral six-month regimen (bedaquiline, delamanid, linezolid, levofloxacin and clofazimine) for multidrug- or rifampicin-resistant TB including pre-XDR disease, plus modified nine-month regimens where fluoroquinolone resistance has been excluded. The changes rest on evidence from the BEAT-Tuberculosis and endTB trials.